NewsRoom Articles - Page 662 of 1389

TuesdayDec 10, 2019 6:40 pm

Milestone Scientific Inc. (MLSS) Starts Presentation at 12th Annual LD Micro Main Event

Milestone Scientific (NYSE: MLSS) is a medical device company that patents, designs, develops and commercializes innovative diagnostic and therapeutic injection technologies and instruments for medical, dental, cosmetic and veterinary applications. Milestone's computer-controlled systems are designed to make injections precise, efficient and virtually painless. Milestone's proprietary DPS Dynamic Pressure Sensing technology® is the company’s technology platform that advances the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions for local anesthesia for subcutaneous drug delivery, with specific applications for cosmetic botulinum toxin injections, epidural space identification in regional anesthesia procedures and…

TuesdayDec 10, 2019 6:20 pm

Sigma Labs Inc. (NASDAQ: SGLB) Starts Presentation at 12th Annual LD Micro Main Event

Sigma Labs (NASDAQ: SGLB) is an emerging provider of quality assurance software to the commercial 3D printing industry under the PrintRite3D® brand. Founded in 2010, Sigma is a software company that specializes in the development and commercialization of real-time computer aided inspection (“CAI”) solutions known as PrintRite3D for 3D advanced-manufacturing technologies. Sigma Labs’ advanced, computer-aided software product revolutionizes commercial additive manufacturing, enabling nondestructive quality assurance mid-production, uniquely allowing errors to be corrected in real time. For more information, visit the company’s website at www.sigmalabsinc.com. About NetworkNewsWire NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation…

TuesdayDec 10, 2019 6:20 pm

Medicenna Therapeutics Corp. (TSX: MDNA) (MDNAF) Starts Presentation at 12th Annual LD Micro Main Event

Medicenna Therapeutics (TSX: MDNA) (OTCQB: MDNAF) is a clinical-stage immunotherapy company focused on oncology and the development and commercialization of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Cytokines™ (ECs) for the treatment of a broad range of cancers. Supported by a US$14.1M non-dilutive grant from CPRIT (Cancer Prevention and Research Institute of Texas), Medicenna's lead IL4-EC, MDNA55, has completed enrolling patients in a Phase 2b clinical trial for rGBM, the most common and uniformly fatal form of brain cancer, at top-ranked brain cancer centers in the U.S. MDNA55 has been studied in…

TuesdayDec 10, 2019 6:20 pm

Perion Network Ltd. (NASDAQ: PERI) Starts Presentation at 12th Annual LD Micro Main Event

Perion Network (NASDAQ: PERI) delivers data-driven online advertising and search solutions to brands and publishers. The company’s high-impact advertising division, Undertone, helps brands capture consumer attention via beautiful creative and proprietary ad formats served across top-tier publishers. Perion’s search division, CodeFuel, enables developers to optimize search traffic and generate incremental revenue. The company’s social advertising platform, MakeMeReach, drives marketing campaigns and demand generation at scale across Facebook, Twitter, Instagram and Snapchat. Perion’s ‘owned and operated’ consumer apps division delivers powerful and engaging mobile and desktop apps direct to consumers. For more information, visit the company’s website at www.perion.com. About NetworkNewsWire…

TuesdayDec 10, 2019 6:20 pm

Dolphin Entertainment Inc. (NASDAQ: DLPN) Starts Presentation at 12th Annual LD Micro Main Event

Dolphin Entertainment (NASDAQ: DLPN) is an independent entertainment marketing and premium content development company. Through its subsidiaries, 42West and The Door, the company provides expert strategic marketing and publicity services to many of the top brands, both individual and corporate, in the entertainment and hospitality industries. Dolphin's recent acquisition of Viewpoint Creative adds full-service creative branding and production capabilities to the company’s marketing group. Dolphin's legacy content production business, founded by Emmy-nominated CEO Bill O'Dowd, has produced multiple feature films and award-winning digital series. For more information, visit the company’s website at www.dolphinentertainment.com. About NetworkNewsWire NetworkNewsWire (NNW) is an information…

TuesdayDec 10, 2019 6:00 pm

LightPath Technologies Inc. (NASDAQ: LPTH) Starts Presentation at 12th Annual LD Micro Main Event

LightPath Technologies (NASDAQ: LPTH) is a global, vertically integrated provider of optics, photonics and infrared solutions for the industrial, commercial, defense, telecommunications and medical industries. LightPath designs, manufactures and distributes proprietary optical and infrared components including molded glass aspheric lenses and assemblies, infrared lenses and thermal imaging assemblies, fused fiber collimators, and proprietary Black DiamondTM (“BD6”) chalcogenide-based glass lenses. LightPath also offers custom optical assemblies, including full engineering design support. The company is headquartered in Orlando, Florida, with manufacturing and sales offices in Latvia and China. For more information, visit the company’s website at www.lightpath.com. About NetworkNewsWire NetworkNewsWire (NNW) is…

TuesdayDec 10, 2019 6:00 pm

U.S. Nuclear Corp. (UCLE) Starts Presentation at 12th Annual LD Micro Main Event

US Nuclear’s (OTCQB: UCLE) operations are principally engaged through its subsidiaries, operating two leading nuclear radiation detection companies, Overhoff Technology Corp. and Optron Scientific Company Inc. The company designs, manufactures and markets branded, full line radiation detection and specialized advanced tritium technology for the nuclear energy industry and for emerging technological processes such as Thorium and Molten Salt (MSR) reactor technologies both domestically and internationally to customers such as United States Government Agencies, the U.S. Military, Homeland Security, Scientific Laboratories, Universities, Hospitals, nuclear reactor facilities in the United States, China, Canada, South Korea, Argentina, Russia, and others. For more information,…

TuesdayDec 10, 2019 6:00 pm

BioLargo Inc. (BLGO) Starts Presentation at 12th Annual LD Micro Main Event

BioLargo (OTCQB: BLGO) invents, patents and develops innovative platform technologies for three markets: advanced water and wastewater treatment, industrial odor and VOC control, and advanced wound care products. With a wide array of issued patents, an extensive R&D talent pool, and a full-service engineering team, the company maintains a robust pipeline of products from inception through maturity. BioLargo monetizes its technology assets with the goal of maximizing both impact and shareholder value, using licensing, strategic partnership, and direct-to-market strategies. For more information, visit the company’s website at www.biolargo.com. About NetworkNewsWire NetworkNewsWire (NNW) is an information service that provides (1) access…

TuesdayDec 10, 2019 5:40 pm

DelMar Pharmaceuticals Inc. (NASDAQ: DMPI) Starts Presentation at 12th Annual LD Micro Main Event

DelMar Pharmaceuticals (NASDAQ: DMPI) is a biopharmaceutical company focused on the development and commercialization of new cancer therapies. The company’s lead product candidate, VAL-083, is a "first-in-class" small molecule DNA-targeting agent that is currently being evaluated in a biomarker-driven, Phase 2 clinical trial for the treatment of Unmethylated MGMT recurrent glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. The company is also exploring VAL-083 in a Phase 2 trial as a therapy for front-line Unmethylated MGMT GBM and we may study other solid tumors, including ovarian cancer and pediatric CNS tumors. For more information, visit the…

TuesdayDec 10, 2019 5:40 pm

Novus Therapeutics Inc. (NASDAQ: NVUS) Starts Presentation at 12th Annual LD Micro Main Event

Novus Therapeutics (NASDAQ: NVUS) is a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose and throat (“ENT”). Novus has two technologies, each that has the potential to be developed for multiple ENT indications. Novus’ lead product candidate (OP0201) is being developed as a potential first-in-class treatment option for patients at risk for, or with, otitis media (“OM”) or middle ear inflammation with or without infection. OM is one of the most common disorders seen in pediatric practice, and in the U.S. it is a leading cause of health care visits; and the most…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

Milestone Scientific Inc. (MLSS) Starts Presentation at 12th Annual LD Micro Main Event

Sigma Labs Inc. (NASDAQ: SGLB) Starts Presentation at 12th Annual LD Micro Main Event

Medicenna Therapeutics Corp. (TSX: MDNA) (MDNAF) Starts Presentation at 12th Annual LD Micro Main Event

Perion Network Ltd. (NASDAQ: PERI) Starts Presentation at 12th Annual LD Micro Main Event

Dolphin Entertainment Inc. (NASDAQ: DLPN) Starts Presentation at 12th Annual LD Micro Main Event

LightPath Technologies Inc. (NASDAQ: LPTH) Starts Presentation at 12th Annual LD Micro Main Event

U.S. Nuclear Corp. (UCLE) Starts Presentation at 12th Annual LD Micro Main Event

BioLargo Inc. (BLGO) Starts Presentation at 12th Annual LD Micro Main Event

DelMar Pharmaceuticals Inc. (NASDAQ: DMPI) Starts Presentation at 12th Annual LD Micro Main Event

Novus Therapeutics Inc. (NASDAQ: NVUS) Starts Presentation at 12th Annual LD Micro Main Event

NetworkNewsWire Currently Accepts

NetworkNewsWire

Financial news and publishing for public and private companies

Contact us: 512.354.7000

NetworkNewsWire Currently Accepts

Company Search

Site Search